• We have a fully funded Phase 3 clinical program in a global partnership for Pracinostat worth up to $464 million.

    Read Our 2017 Annual Review

  • Emerging data positions our second drug candidate, a highly differentiated PI3K delta inhibitor, toward a pivotal study in the coming year.

    Read Our 2017 Annual Review

  • Our newest asset, a selective CDK inhibitor with potent inhibition of CDK9, addresses resistance to potential blockbuster drug Venclexta.

    Read Our 2017 Annual Review

  • We are led by a world-class management team with proven experience in oncology drug development, from discovery to approval.

    Read Our 2017 Annual Review

LATEST NEWS

MEI Pharma to Host Annual Meeting of Stockholders
Press Release | Webcast


MEI Pharma Reports First Quarter Fiscal Year 2018 Results
Press Release


Presentation at Stifel 2017 Healthcare Conference

Press Release | Webcast


Presentation at Cantor Global Healthcare Conference
Webast

 


Exclusive License Agreement with Presage Biosciences for Voruciclib
Press Release